Cell Therapies Forge Ahead In Japan with Reimbursement, Approval Decisions
A controversial cell therapy for spinal injuries receives coverage under Japan’s national health scheme, amid signs that the pricing of regenerative therapies may come under more scrutiny, while the first CAR-T treatment in the country takes a step closer to market.
You may also be interested in...
Looking back on the top stories about Japan in Scrip and the Pink Sheet over 2019, it is hard to avoid the continued dominance of corporate transactions - in particular those involving Takeda.
Novartis CAR-T therapy becomes most expensive drug ever covered by Japan’s national health insurance system. Although authorities expect total sales to be modest, might high price again raise official concerns over ballooning health costs?
Activity in Japan's cell and regenerative therapy space continues apace as venture starts trial with lead development asset for acute respiratory distress syndrome.